» Authors » Huiman Barnhart

Huiman Barnhart

Explore the profile of Huiman Barnhart including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 67
Citations 2543
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Ibemere S, Barnhart H, Myers J, Miller J, Osunkwo I, Bosworth H, et al.
J Emerg Nurs . 2025 Feb; PMID: 40019423
Introduction: National guidelines for the acute management of sickle cell disease vaso-occlusive episodes recommend the use of a patient-specific or a weight-based protocol. The authors compared patient satisfaction with pain...
2.
Bentley-Edwards K, Glover L, Johnson A, Mohottige D, Obayemi J, Olague S, et al.
J Am Soc Nephrol . 2025 Jan; PMID: 39851186
No abstract available.
3.
Barritt 4th A, Hayashi P, Stolz A, Barnhart H, Hoofnagle J
Am J Gastroenterol . 2024 Oct; PMID: 39422332
Introduction: Hyman Zimmerman observed that hepatocellular (HC) drug-induced liver injury (DILI) with jaundice had a mortality rate of ≥ 10% (Hy Law). Hy Law does not specify the timing of...
4.
Halegoua-DeMarzio D, Navarro V, Davis A, Ahmad J, Avula B, Barnhart H, et al.
Drug Saf . 2024 Oct; 48(2):143-150. PMID: 39354283
Background:  The attribution of drug-induced liver injury (DILI) to specific herbal and dietary supplements (HDS) is confounded by inaccurate labels and undisclosed ingredients. The US Drug-Induced Liver Injury Network (DILIN)...
5.
Chen V, Rockey D, Bjornsson E, Barnhart H, Hoofnagle J
Drug Saf . 2024 Sep; 48(2):151-160. PMID: 39317916
Background: The incidence of drug-induced liver injury (DILI) is not known for most prescription medications. We aimed to estimate the incidence of DILI for commonly prescribed outpatient drugs. Methods: To...
6.
Fontana R, Li Y, Chen V, Kleiner D, Stolz A, Odin J, et al.
Hepatol Commun . 2024 Aug; 8(9). PMID: 39185906
Background: The clinical features, liver histology, and genetic variants in 57 patients with moderate to severe immune-mediated liver injury from checkpoint inhibitors (ILICI) are presented. Methods: Between 2010 and 2022,...
7.
Bosworth H, Patel U, Lewinski A, Davenport C, Pendergast J, Oakes M, et al.
Med Care . 2024 Jul; 62(10):660-666. PMID: 39038105
Background/objective: Slowing the progression of diabetic kidney disease (DKD) is critical. We conducted a randomized controlled trial to target risk factors for DKD progression. Methods: We evaluated the effect of...
8.
Conlon C, Li Y, Ahmad J, Barnhart H, Fontana R, Ghabril M, et al.
Aliment Pharmacol Ther . 2024 Jul; 60(6):787-795. PMID: 38988034
Background: Azithromycin (AZ) is a widely used antibiotic. The aim of this study was to characterise the clinical features, outcomes, and HLA association in patients with drug-induced liver injury (DILI)...
9.
Choi G, Ahmad J, Navarro V, Thung S, Khan I, Avula B, et al.
Aliment Pharmacol Ther . 2024 Jun; 60(4):479-483. PMID: 38874448
Background: In April 2022, French Lentil and Leek Crumble (FLLC), a new frozen food preparation manufactured by Daily Harvest™ (containing Tara flour) was offered as a natural high-protein meal product....
10.
Masood U, Venturini N, Nicoletti P, Dellinger A, Kleiner D, Bonkovsky H, et al.
Obstet Gynecol . 2024 Apr; 143(6):819-823. PMID: 38626448
There are limited data on the causative agents and characteristics of drug-induced liver injury in pregnant individuals. Data from patients with drug-induced liver injury enrolled in the ongoing multicenter Drug-Induced...